Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.

Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr.

Ann Intern Med. 2005 Jan 18;142(2):95-104.

PMID:
15657157
3.

Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels.

[No authors listed]

Ann Intern Med. 2005 Jan 18;142(2):I46. No abstract available.

PMID:
15657152
4.

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.

N Engl J Med. 1999 Aug 5;341(6):410-8.

5.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

JAMA. 1998 May 27;279(20):1615-22.

PMID:
9613910
6.

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial.

JAMA. 2001 Mar 28;285(12):1585-91.

PMID:
11268266
8.

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W.

N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15. Erratum in: N Engl J Med. 2012 Jul 12;367(2):189.

9.

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.

Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD.

Arch Intern Med. 2000 Apr 24;160(8):1177-84.

PMID:
10789612
10.

[Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS].

Rensing UF, Bestehorn HP, Roskamm H, Petersen J, Betz P, Spinder M, Benesch L, Schemeitat K, Blümchen G, Claus J, Wieland H, Böcker JF, Neiss A, Stiepel E, Mathes P, Kappenberger L, Braunagel K, Peters K, Meister G, Samek L, Schuon J, Leimenstoll B, Kiefer H.

Z Kardiol. 1999 Apr;88(4):270-82. German.

PMID:
10408031
13.

The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.

Krasuski RA, Devendra GP, Cater G, Whitney EJ.

Am J Med Sci. 2011 May;341(5):378-82. doi: 10.1097/MAJ.0b013e318209d851.

PMID:
21358314
14.

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE.

J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.

16.

Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.

Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD Jr, Balagtas CC, Rowan JP, Black DM.

Atherosclerosis. 1996 Nov 15;127(1):113-22.

PMID:
9006811
17.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
18.

Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.

Kim SH, Kim MK, Lee HY, Kang HJ, Kim YJ, Park BJ, Kim HS.

Clin Ther. 2011 Oct;33(10):1357-64. doi: 10.1016/j.clinthera.2011.08.015. Epub 2011 Sep 28.

PMID:
21955937
19.

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ.

N Engl J Med. 2001 Nov 29;345(22):1583-92.

20.

Low-density lipoprotein apheresis: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk